Introduction Humira is the brand name of adalimumab, a biologic immunomodulatory medicine that belongs to the tumor necrosis factor blocker class. More specifically, adalimumab is a recombinant human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha, commonly abbreviated as TNF-α. TNF-α is a pro-inflammatory cytokine with an important role in normal immune defense. When produced … Read more
Introduction Cimzia is the brand name of certolizumab pegol, a biologic anti-inflammatory drug used in several immune-mediated inflammatory diseases. Pharmacologically, Cimzia is a tumor necrosis factor blocker, commonly called a TNF inhibitor or anti-TNF drug. Tumor necrosis factor-alpha, or TNF-alpha, is a major pro-inflammatory cytokine involved in immune-cell activation, cytokine release, leukocyte migration, endothelial activation, … Read more
Mechanism of Action of Taltz Introduction Taltz is the brand name of ixekizumab, a biologic immunomodulator used in selected chronic inflammatory diseases. Pharmacologically, ixekizumab is a humanized immunoglobulin G4 monoclonal antibody that acts as an interleukin-17A antagonist. Interleukin-17A, commonly called IL-17A, is a pro-inflammatory cytokine involved in normal immune defense and abnormal immune-mediated inflammation. It … Read more
Introduction Enbrel is the brand name of etanercept, a biologic disease-modifying antirheumatic drug used in several chronic inflammatory autoimmune diseases. Pharmacologically, etanercept is a tumor necrosis factor blocker, commonly called a TNF inhibitor or anti-TNF drug. Tumor necrosis factor, especially TNF-alpha, is a major pro-inflammatory cytokine involved in immune activation, leukocyte migration, synovial inflammation, cartilage … Read more
Introduction Secukinumab is a biologic immunomodulator marketed under the brand name Cosentyx. Pharmacologically, it is a human interleukin-17A antagonist and a recombinant human IgG1 kappa monoclonal antibody. Interleukin-17A, commonly called IL-17A, is a pro-inflammatory cytokine involved in immune defense and chronic inflammatory disease. It is produced mainly by Th17 cells, but other immune cells such … Read more
Introduction Guselkumab is a biologic immunomodulator used in inflammatory immune-mediated diseases. It is marketed under the brand name Tremfya. Pharmacologically, guselkumab is an interleukin-23 antagonist and a human IgG1 lambda monoclonal antibody. Interleukin-23, commonly called IL-23, is an important cytokine involved in chronic inflammation. It plays a major role in the activation and maintenance of … Read more
Introduction Cosentyx is the brand name of secukinumab, a fully human monoclonal antibody used in immune-mediated inflammatory diseases. It belongs to the class of interleukin-17A inhibitors, also called IL-17A antagonists. Cosentyx is important in pharmacology because it targets a specific inflammatory cytokine rather than producing broad immunosuppression like corticosteroids. It is used in conditions where … Read more
Mechanism of Action of Otezla (Apremilast) Introduction Otezla is the brand name for apremilast, an oral phosphodiesterase-4 (PDE4) inhibitor used for the treatment of plaque psoriasis, psoriatic arthritis, oral ulcers associated with Behçet’s disease, and other inflammatory conditions. Unlike biologic therapies that target specific cytokines, apremilast works intracellularly by modulating inflammatory signaling pathways through cyclic … Read more
Introduction Adalimumab is a fully human monoclonal IgG1 antibody that specifically targets tumor necrosis factor‑α (TNF‑α). By neutralizing TNF‑α, it reduces inflammation across a variety of autoimmune conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease, ulcerative colitis, and plaque psoriasis. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Subcutaneous … Read more
Introduction Etanercept is a biologic fusion protein that functions as a soluble tumor necrosis factor (TNF) receptor. By binding TNF-α and TNF-β in circulation, it blocks their interaction with cell surface receptors, reducing systemic inflammation. It is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and plaque psoriasis. … Read more
